• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Benzinga's Top Ratings Upgrades, Downgrades For June 1, 2022

    6/1/22 10:08:32 AM ET
    $AOMR
    $BPMC
    $CF
    $CTT
    Real Estate
    Finance
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AOMR alert in real time by email

    Upgrades

    Citigroup upgraded the previous rating for FinVolution Group (NYSE:FINV) from Neutral to Buy. FinVolution Gr earned $0.30 in the first quarter, compared to $0.31 in the year-ago quarter. The stock has a 52-week-high of $10.41 and a 52-week-low of $2.68. At the end of the last trading period, FinVolution Gr closed at $4.21.

    For Noble Corp (NYSE:NE), BTIG upgraded the previous rating of Neutral to Buy. At the moment, the stock has a 52-week-high of $37.77 and a 52-week-low of $20.34. Noble closed at $36.28 at the end of the last trading period.

    For Vertex Pharmaceuticals Inc (NASDAQ:VRTX), Maxim Group upgraded the previous rating of Hold to Buy. For the first quarter, Vertex Pharmaceuticals had an EPS of $3.52, compared to year-ago quarter EPS of $2.98. The stock has a 52-week-high of $292.75 and a 52-week-low of $176.36. At the end of the last trading period, Vertex Pharmaceuticals closed at $268.65.

    For Visteon Corp (NASDAQ:VC), Morgan Stanley upgraded the previous rating of Underweight to Equal-Weight. Visteon earned $1.09 in the first quarter, compared to $0.56 in the year-ago quarter. At the moment, the stock has a 52-week-high of $134.57 and a 52-week-low of $88.82. Visteon closed at $112.21 at the end of the last trading period.

    For Home Bancorp Inc (NASDAQ:HBCP), DA Davidson upgraded the previous rating of Neutral to Buy. Home Bancorp earned $0.53 in the first quarter, compared to $1.41 in the year-ago quarter. At the moment, the stock has a 52-week-high of $45.73 and a 52-week-low of $33.16. Home Bancorp closed at $34.39 at the end of the last trading period.

    For Park Hotels & Resorts Inc (NYSE:PK), Truist Securities upgraded the previous rating of Hold to Buy. Park Hotels & Resorts earned $0.08 in the first quarter, compared to $0.48 in the year-ago quarter. At the moment, the stock has a 52-week-high of $22.42 and a 52-week-low of $15.57. Park Hotels & Resorts closed at $18.06 at the end of the last trading period.

    Cowen & Co. upgraded the previous rating for Xylem Inc (NYSE:XYL) from Underperform to Market Perform. In the first quarter, Xylem showed an EPS of $0.47, compared to $0.56 from the year-ago quarter. At the moment, the stock has a 52-week-high of $138.78 and a 52-week-low of $78.92. Xylem closed at $84.25 at the end of the last trading period.

    For Blueprint Medicines Corp (NASDAQ:BPMC), Jefferies upgraded the previous rating of Hold to Buy. In the first quarter, Blueprint Medicines showed an EPS of $1.79, compared to $1.72 from the year-ago quarter. At the moment, the stock has a 52-week-high of $117.86 and a 52-week-low of $50.95. Blueprint Medicines closed at $55.00 at the end of the last trading period.

    RBC Capital upgraded the previous rating for Danaher Corp (NYSE:DHR) from Sector Perform to Outperform. Danaher earned $2.76 in the first quarter, compared to $2.52 in the year-ago quarter. The current stock performance of Danaher shows a 52-week-high of $333.96 and a 52-week-low of $233.71. Moreover, at the end of the last trading period, the closing price was at $263.82.

    For Enanta Pharmaceuticals Inc (NASDAQ:ENTA), Evercore ISI Group upgraded the previous rating of Underperform to In-Line. In the second quarter, Enanta Pharmaceuticals showed an EPS of $1.63, compared to $1.09 from the year-ago quarter. At the moment, the stock has a 52-week-high of $102.00 and a 52-week-low of $37.59. Enanta Pharmaceuticals closed at $39.93 at the end of the last trading period.

    For CatchMark Timber Trust Inc (NYSE:CTT), Raymond James upgraded the previous rating of Underperform to Market Perform. CatchMark Timber Trust earned $0.07 in the first quarter, compared to $0.01 in the year-ago quarter. The stock has a 52-week-high of $12.57 and a 52-week-low of $7.18. At the end of the last trading period, CatchMark Timber Trust closed at $11.79.

    See all analyst ratings upgrades.

    Downgrades

    Redburn Partners downgraded the previous rating for Valero Energy Corp (NYSE:VLO) from Buy to Neutral. In the first quarter, Valero Energy showed an EPS of $2.31, compared to $1.73 from the year-ago quarter. The stock has a 52-week-high of $135.75 and a 52-week-low of $58.85. At the end of the last trading period, Valero Energy closed at $129.60.

    According to UBS, the prior rating for Angel Oak Mortgage Inc (NYSE:AOMR) was changed from Buy to Neutral. Angel Oak Mortgage earned $1.49 in the first quarter, compared to $0.60 in the year-ago quarter. The current stock performance of Angel Oak Mortgage shows a 52-week-high of $19.00 and a 52-week-low of $12.60. Moreover, at the end of the last trading period, the closing price was at $15.30.

    For Poshmark Inc (NASDAQ:POSH), JMP Securities downgraded the previous rating of Market Outperform to Market Perform. Poshmark earned $0.18 in the first quarter, compared to $0.33 in the year-ago quarter. The stock has a 52-week-high of $52.39 and a 52-week-low of $8.97. At the end of the last trading period, Poshmark closed at $10.93.

    For 1stdibs.com Inc (NASDAQ:DIBS), JMP Securities downgraded the previous rating of Market Outperform to Market Perform. At the moment, the stock has a 52-week-high of $35.46 and a 52-week-low of $4.77. 1stdibs.com closed at $5.71 at the end of the last trading period.

    According to Wells Fargo, the prior rating for Fortis Inc (NYSE:FTS) was changed from Equal-Weight to Underweight. In the first quarter, Fortis showed an EPS of $0.62, compared to $0.61 from the year-ago quarter. The stock has a 52-week-high of $51.66 and a 52-week-low of $43.12. At the end of the last trading period, Fortis closed at $50.36.

    Baird downgraded the previous rating for GoodRx Holdings Inc (NASDAQ:GDRX) from Outperform to Neutral. GoodRx Holdings earned $0.10 in the first quarter, compared to $0.07 in the year-ago quarter. The current stock performance of GoodRx Holdings shows a 52-week-high of $48.05 and a 52-week-low of $7.33. Moreover, at the end of the last trading period, the closing price was at $7.97.

    For Gates Industrial Corp PLC (NYSE:GTES), RBC Capital downgraded the previous rating of Outperform to Sector Perform. For the first quarter, Gates Industrial Corp had an EPS of $0.26, compared to year-ago quarter EPS of $0.33. The current stock performance of Gates Industrial Corp shows a 52-week-high of $18.94 and a 52-week-low of $11.57. Moreover, at the end of the last trading period, the closing price was at $12.76.

    For Medtronic PLC (NYSE:MDT), Atlantic Equities downgraded the previous rating of Overweight to Neutral. For the fourth quarter, Medtronic had an EPS of $1.52, compared to year-ago quarter EPS of $1.50. At the moment, the stock has a 52-week-high of $135.89 and a 52-week-low of $96.86. Medtronic closed at $100.15 at the end of the last trading period.

    For CatchMark Timber Trust Inc (NYSE:CTT), Stifel downgraded the previous rating of Buy to Hold. For the first quarter, CatchMark Timber Trust had an EPS of $0.07, compared to year-ago quarter EPS of $0.01. At the moment, the stock has a 52-week-high of $12.57 and a 52-week-low of $7.18. CatchMark Timber Trust closed at $11.79 at the end of the last trading period.

    For Sealed Air Corp (NYSE:SEE), JP Morgan downgraded the previous rating of Neutral to Underweight. Sealed Air earned $1.12 in the first quarter, compared to $0.78 in the year-ago quarter. The stock has a 52-week-high of $70.72 and a 52-week-low of $53.87. At the end of the last trading period, Sealed Air closed at $62.18.

    For Sibanye Stillwater Ltd (NYSE:SBSW), RBC Capital downgraded the previous rating of Outperform to Sector Perform. NoneThe stock has a 52-week-high of $20.64 and a 52-week-low of $10.51. At the end of the last trading period, Sibanye Stillwater closed at $12.99.

    For Tempur Sealy International Inc (NYSE:TPX), Piper Sandler downgraded the previous rating of Overweight to Neutral. Tempur Sealy Intl earned $0.69 in the first quarter, compared to $0.64 in the year-ago quarter. The current stock performance of Tempur Sealy Intl shows a 52-week-high of $50.51 and a 52-week-low of $23.28. Moreover, at the end of the last trading period, the closing price was at $26.37.

    For Patterson-UTI Energy Inc (NASDAQ:PTEN), Piper Sandler downgraded the previous rating of Overweight to Neutral. For the first quarter, Patterson-UTI Energy had an EPS of $0.13, compared to year-ago quarter EPS of $0.57. The current stock performance of Patterson-UTI Energy shows a 52-week-high of $20.53 and a 52-week-low of $6.44. Moreover, at the end of the last trading period, the closing price was at $19.08.

    See all analyst ratings downgrades.

    Initiations

    Citigroup initiated coverage on Shattuck Labs Inc (NASDAQ:STTK) with a Buy rating. The price target for Shattuck Labs is set to $13.00. Shattuck Labs earned $0.58 in the first quarter, compared to $0.28 in the year-ago quarter. The stock has a 52-week-high of $31.23 and a 52-week-low of $2.59. At the end of the last trading period, Shattuck Labs closed at $2.86.

    EF Hutton initiated coverage on Tetra Technologies Inc (NYSE:TTI) with a Buy rating. The price target for Tetra Technologies is set to $8.00. Tetra Technologies earned $0.06 in the first quarter, compared to $0.04 in the year-ago quarter. The stock has a 52-week-high of $5.61 and a 52-week-low of $2.32. At the end of the last trading period, Tetra Technologies closed at $5.02.

    Alliance Global Partners initiated coverage on Enveric Biosciences Inc (NASDAQ:ENVB) with a Buy rating. The price target for Enveric Biosciences is set to $1.25. In the first quarter, Enveric Biosciences showed an EPS of $0.11, compared to $0.20 from the year-ago quarter. At the moment, the stock has a 52-week-high of $3.74 and a 52-week-low of $0.17. Enveric Biosciences closed at $0.20 at the end of the last trading period.

    With a Buy rating, UBS initiated coverage on SSR Mining Inc (NASDAQ:SSRM). The price target seems to have been set at $22.00 for SSR Mining. In the first quarter, SSR Mining showed an EPS of $0.30, compared to $0.47 from the year-ago quarter. The stock has a 52-week-high of $24.58 and a 52-week-low of $14.19. At the end of the last trading period, SSR Mining closed at $19.43.

    With a Equal-Weight rating, Barclays initiated coverage on ICL Group Ltd (NYSE:ICL). The price target seems to have been set at $12.00 for ICL Group. ICL Group earned $0.47 in the first quarter, compared to $0.11 in the year-ago quarter. The stock has a 52-week-high of $12.96 and a 52-week-low of $6.43. At the end of the last trading period, ICL Group closed at $10.98.

    With an Underweight rating, Barclays initiated coverage on The Mosaic Co (NYSE:MOS). The price target seems to have been set at $59.00 for Mosaic. For the first quarter, Mosaic had an EPS of $2.41, compared to year-ago quarter EPS of $0.57. The stock has a 52-week-high of $79.28 and a 52-week-low of $28.26. At the end of the last trading period, Mosaic closed at $62.65.

    Barclays initiated coverage on CF Industries Holdings Inc (NYSE:CF) with a Equal-Weight rating. The price target for CF Industries Holdings is set to $103.00. In the first quarter, CF Industries Holdings showed an EPS of $4.21, compared to $0.70 from the year-ago quarter. At the moment, the stock has a 52-week-high of $113.48 and a 52-week-low of $43.19. CF Industries Holdings closed at $98.77 at the end of the last trading period.

    With an Overweight rating, Barclays initiated coverage on Corteva Inc (NYSE:CTVA). The price target seems to have been set at $71.00 for Corteva. Corteva earned $0.97 in the first quarter, compared to $0.79 in the year-ago quarter. The stock has a 52-week-high of $64.03 and a 52-week-low of $40.60. At the end of the last trading period, Corteva closed at $62.62.

    With an Overweight rating, Barclays initiated coverage on Nutrien Ltd (NYSE:NTR). The price target seems to have been set at $116.00 for Nutrien. Nutrien earned $2.70 in the first quarter, compared to $0.29 in the year-ago quarter. The current stock performance of Nutrien shows a 52-week-high of $117.25 and a 52-week-low of $57.08. Moreover, at the end of the last trading period, the closing price was at $97.19.

    With a Buy rating, BTIG initiated coverage on NexImmune Inc (NASDAQ:NEXI). The price target seems to have been set at $5.00 for NexImmune. In the first quarter, NexImmune showed an EPS of $0.66, compared to $0.71 from the year-ago quarter. The current stock performance of NexImmune shows a 52-week-high of $19.37 and a 52-week-low of $1.72. Moreover, at the end of the last trading period, the closing price was at $2.28.

    JMP Securities initiated coverage on Etsy Inc (NASDAQ:ETSY) with a Market Outperform rating. The price target for Etsy is set to $125.00. Etsy earned $0.60 in the first quarter, compared to $1.00 in the year-ago quarter. At the moment, the stock has a 52-week-high of $307.75 and a 52-week-low of $68.40. Etsy closed at $81.12 at the end of the last trading period.

    Cantor Fitzgerald initiated coverage on Gracell Biotechnologies Inc (NASDAQ:GRCL) with an Overweight rating. The price target for Gracell Biotechnologies is set to $20.00. Gracell Biotechnologies earned $0.35 in the first quarter, compared to $0.25 in the year-ago quarter. The current stock performance of Gracell Biotechnologies shows a 52-week-high of $16.93 and a 52-week-low of $1.68. Moreover, at the end of the last trading period, the closing price was at $3.29.

    With a Neutral rating, Credit Suisse initiated coverage on Squarespace Inc (NYSE:SQSP). The price target seems to have been set at $25.00 for Squarespace. For the first quarter, Squarespace had an EPS of $0.67, compared to year-ago quarter EPS of $0.11. At the moment, the stock has a 52-week-high of $64.71 and a 52-week-low of $14.43. Squarespace closed at $20.59 at the end of the last trading period.

    BMO Capital initiated coverage on MP Materials Corp (NYSE:MP) with an Outperform rating. The price target for MP Materials is set to $50.00. In the first quarter, MP Materials showed an EPS of $0.50, compared to $0.13 from the year-ago quarter. The current stock performance of MP Materials shows a 52-week-high of $60.19 and a 52-week-low of $27.56. Moreover, at the end of the last trading period, the closing price was at $39.43.

    See all analyst ratings initiations.

    Get the next $AOMR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AOMR
    $BPMC
    $CF
    $CTT

    CompanyDatePrice TargetRatingAnalyst
    Corteva Inc.
    $CTVA
    2/9/2026$80.00Buy → Neutral
    UBS
    Medtronic plc.
    $MDT
    2/9/2026$121.00Hold → Buy
    Needham
    Corteva Inc.
    $CTVA
    2/5/2026$77.00Overweight → Neutral
    Analyst
    CF Industries Holdings Inc.
    $CF
    2/4/2026$72.00Neutral → Sell
    Rothschild & Co Redburn
    Medtronic plc.
    $MDT
    2/3/2026$117.00Buy
    Citigroup
    Mosaic Company
    $MOS
    2/2/2026$36.00Sector Perform → Sector Outperform
    Scotiabank
    Medtronic plc.
    $MDT
    1/30/2026$114.00Overweight
    Wells Fargo
    Home Bancorp Inc.
    $HBCP
    1/29/2026$61.00 → $62.00Market Perform
    Hovde Group
    More analyst ratings

    $AOMR
    $BPMC
    $CF
    $CTT
    SEC Filings

    View All

    Gates Industrial Corporation plc filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Gates Industrial Corp plc (0001718512) (Filer)

    2/12/26 7:39:17 AM ET
    $GTES
    Industrial Machinery/Components
    Industrials

    SEC Form 6-K filed by Fortis Inc.

    6-K - Fortis Inc. (0001666175) (Filer)

    2/12/26 7:22:40 AM ET
    $FTS
    Electric Utilities: Central
    Utilities

    SEC Form 6-K filed by Fortis Inc.

    6-K - Fortis Inc. (0001666175) (Filer)

    2/12/26 6:07:19 AM ET
    $FTS
    Electric Utilities: Central
    Utilities

    $AOMR
    $BPMC
    $CF
    $CTT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Gates Industrial Reports Fourth-Quarter and Full Year 2025 Results

    DENVER, Feb. 12, 2026 /PRNewswire/ --  Fourth-Quarter 2025 Financial Summary Fourth-quarter net sales of $856.2 million, up 3.2% compared to the prior-year period, including a core sales growth of 0.6%Net income attributable to shareholders of $51.3 million, or $0.20 per diluted shareAdjusted Net Income per diluted share of $0.38Net income from continuing operations of $56.4 million, or a margin of 6.6%Adjusted EBITDA of $187.8 million, or a margin of 21.9%Repurchased approximately $105 million of sharesFull-Year 2025 Financial Summary Net sales of $3,443.2 million, representi

    2/12/26 7:30:00 AM ET
    $GTES
    Industrial Machinery/Components
    Industrials

    Fortis Inc. Files 2025 Year-End Disclosure Documents

    This news release constitutes a "Designated News Release" incorporated by reference in the prospectus supplement dated December 9, 2024 to Fortis' short form base shelf prospectus dated December 9, 2024. ST. JOHN'S, Newfoundland and Labrador, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Fortis Inc. ("Fortis" or the "Corporation") (TSX/NYSE:FTS), today filed its audited Consolidated Financial Statements, related Management Discussion and Analysis and Form 40-F for the year ended December 31, 2025, as well as its 2025 Annual Information Form, with Canadian securities regulatory authorities. The Corporation also filed its Form 40-F for the year ended December 31, 2025 with the U.S. Securities and Excha

    2/12/26 7:17:46 AM ET
    $FTS
    Electric Utilities: Central
    Utilities

    Fortis Inc. Reports Fourth Quarter & Annual 2025 Results

    This news release constitutes a "Designated News Release" incorporated by reference in the prospectus supplement dated December 9, 2024 to Fortis' short form base shelf prospectus dated December 9, 2024. ST. JOHN'S, Newfoundland and Labrador, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Fortis Inc. ("Fortis" or the "Corporation") (TSX/NYSE:FTS), a diversified leader in the North American regulated electric and gas utility industry, released its 2025 fourth quarter and annual financial results.1 Highlights Annual net earnings of $1.7 billion, or $3.40 per common share for 2025Annual adjusted net earnings per common share2 of $3.53, up from $3.28 for 2024Capital expenditures2 of $5.6 billion,

    2/12/26 6:00:00 AM ET
    $FTS
    Electric Utilities: Central
    Utilities

    $AOMR
    $BPMC
    $CF
    $CTT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    January 30, 2025 - FDA Approves Novel Non-Opioid Treatment for Moderate to Severe Acute Pain

    For Immediate Release: January 30, 2025 Today, the U.S. Food and Drug Administration approved Journavx (suzetrigine) 50 milligram oral tablets, a first-in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals reach the brain.  Journavx is the first dr

    1/30/25 5:46:14 PM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    December 8, 2023 - FDA Approves First Gene Therapies to Treat Patients with Sickle Cell Disease

    For Immediate Release: December 08, 2023 Today, the U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signali

    12/8/23 11:12:21 AM ET
    $BLUE
    $VRTX
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    FDA Approval for TRIKAFTA (COPACKAGED) issued to VERTEX PHARMS INC

    Submission status for VERTEX PHARMS INC's drug TRIKAFTA (COPACKAGED) (SUPPL-11) with active ingredient ELEXACAFTOR, IVACAFTOR, TEZACAFTOR; IVACAFTOR has changed to 'Approval' on 08/03/2023. Application Category: NDA, Application Number: 212273, Application Classification: Labeling

    8/4/23 4:36:00 AM ET
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AOMR
    $BPMC
    $CF
    $CTT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kelly Christie B. bought $33,008 worth of shares (2,949 units at $11.19), increasing direct ownership by 2% to 150,501 units (SEC Form 4)

    4 - Park Hotels & Resorts Inc. (0001617406) (Issuer)

    1/16/26 4:39:43 PM ET
    $PK
    Hotels/Resorts
    Consumer Discretionary

    Director Kuzenko Jody Lynne bought $17,488 worth of shares (685 units at $25.53), increasing direct ownership by 9% to 8,571 units (SEC Form 4)

    4 - MOSAIC CO (0001285785) (Issuer)

    11/13/25 4:01:46 PM ET
    $MOS
    Agricultural Chemicals
    Industrials

    Director Orbimed Advisors Llc bought $5,471,826 worth of shares (6,306,127 units at $0.87) (SEC Form 4)

    4 - Shattuck Labs, Inc. (0001680367) (Issuer)

    9/2/25 9:52:10 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AOMR
    $BPMC
    $CF
    $CTT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Corteva downgraded by UBS with a new price target

    UBS downgraded Corteva from Buy to Neutral and set a new price target of $80.00

    2/9/26 6:59:50 AM ET
    $CTVA
    Farming/Seeds/Milling
    Consumer Staples

    Medtronic upgraded by Needham with a new price target

    Needham upgraded Medtronic from Hold to Buy and set a new price target of $121.00

    2/9/26 6:45:10 AM ET
    $MDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Corteva downgraded by Analyst with a new price target

    Analyst downgraded Corteva from Overweight to Neutral and set a new price target of $77.00

    2/5/26 6:53:33 AM ET
    $CTVA
    Farming/Seeds/Milling
    Consumer Staples

    $AOMR
    $BPMC
    $CF
    $CTT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 5 filed by Zollinger John J. Iv

    5 - HOME BANCORP, INC. (0001436425) (Issuer)

    2/10/26 7:34:22 PM ET
    $HBCP
    Banks
    Finance

    SEC Form 5 filed by Kirkley David T.

    5 - HOME BANCORP, INC. (0001436425) (Issuer)

    2/10/26 7:24:02 PM ET
    $HBCP
    Banks
    Finance

    SEC Form 5 filed by Herpin Mark C

    5 - HOME BANCORP, INC. (0001436425) (Issuer)

    2/10/26 7:10:09 PM ET
    $HBCP
    Banks
    Finance

    $AOMR
    $BPMC
    $CF
    $CTT
    Leadership Updates

    Live Leadership Updates

    View All

    Satellos Appoints Antoinette Paone as Chief Development Officer and Head of Regulatory Affairs

    Experienced industry leader brings extensive expertise in leading breakthrough therapies through clinical development to marketing approval Satellos Bioscience Inc. (TSX:MSCL, OTCQB:MSCLF) ("Satellos" or the "Company"), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, today announced the appointment of Antoinette Paone as Chief Development Officer ("CDO") and Head of Regulatory Affairs. Ms. Paone brings extensive experience leading regulatory strategy from clinical development through approval, including her work on Kalydeco and Orkambi at Vertex Pharmaceuticals (NASDAQ:VRTX). She joins Satellos from Generation Bio (NASDAQ:G

    1/29/26 7:00:00 AM ET
    $GBIO
    $VRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Critical Minerals Take Center Stage as U.S. Accelerates Push for Domestic Supply Security

    NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) -- The Western world is entering a strategic race to secure domestic supplies of critical minerals, creating a compelling opportunity set for investors focused on resource security and long-term value for active miners that include Military Metals Corp. (OTCQB:MILIF) (CSE:MILI), Perpetua Resources Corp. (NASDAQ:PPTA) (TSX:PPTA), United States Antimony Corporation (NYSE:UAMY), MP Materials Corp. (NYSE:MP), Critical Metals Corp. (NASDAQ:CRML). Antimony and gold are moving to the forefront as strategically vital materials: antimony for defense systems, semiconductors, and advanced energy applications, and gold for financial stability, electronics, and

    1/7/26 8:45:00 AM ET
    $CRML
    $MP
    $PPTA
    Metal Mining
    Basic Materials
    Precious Metals
    Metal Fabrications

    Etsy Announces New $750 Million Share Repurchase Authorization and appointment of Fred Wilson as Lead Independent Director

    BROOKLYN, N.Y., Dec. 18, 2025 /PRNewswire/ -- Etsy, Inc. (NYSE:ETSY), the global marketplace for unique and creative goods, today announced that its Board of Directors has approved a new $750 million share repurchase authorization. When combined with the estimated remaining capacity of over $200 million1 under the Company's existing share repurchase Board authorization, Etsy will have authorization for close to $1 billion of potential future share repurchases. In addition, the Board has appointed the current Chair of the Board, Fred Wilson, as Lead Independent Director effective January 1, 2026. The appointment follows the previously announced leadership transition in which Kruti Patel Goya

    12/18/25 7:00:00 AM ET
    $ETSY
    Real Estate

    $AOMR
    $BPMC
    $CF
    $CTT
    Financials

    Live finance-specific insights

    View All

    Gates Industrial Reports Fourth-Quarter and Full Year 2025 Results

    DENVER, Feb. 12, 2026 /PRNewswire/ --  Fourth-Quarter 2025 Financial Summary Fourth-quarter net sales of $856.2 million, up 3.2% compared to the prior-year period, including a core sales growth of 0.6%Net income attributable to shareholders of $51.3 million, or $0.20 per diluted shareAdjusted Net Income per diluted share of $0.38Net income from continuing operations of $56.4 million, or a margin of 6.6%Adjusted EBITDA of $187.8 million, or a margin of 21.9%Repurchased approximately $105 million of sharesFull-Year 2025 Financial Summary Net sales of $3,443.2 million, representi

    2/12/26 7:30:00 AM ET
    $GTES
    Industrial Machinery/Components
    Industrials

    Fortis Inc. Reports Fourth Quarter & Annual 2025 Results

    This news release constitutes a "Designated News Release" incorporated by reference in the prospectus supplement dated December 9, 2024 to Fortis' short form base shelf prospectus dated December 9, 2024. ST. JOHN'S, Newfoundland and Labrador, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Fortis Inc. ("Fortis" or the "Corporation") (TSX/NYSE:FTS), a diversified leader in the North American regulated electric and gas utility industry, released its 2025 fourth quarter and annual financial results.1 Highlights Annual net earnings of $1.7 billion, or $3.40 per common share for 2025Annual adjusted net earnings per common share2 of $3.53, up from $3.28 for 2024Capital expenditures2 of $5.6 billion,

    2/12/26 6:00:00 AM ET
    $FTS
    Electric Utilities: Central
    Utilities

    Fortis Inc. Announces Second Quarter Dividends – 2026

    This news release constitutes a "Designated News Release" incorporated by reference in the prospectus supplement dated December 9, 2024 to Fortis' short form base shelf prospectus dated December 9, 2024. ST. JOHN'S, Newfoundland and Labrador, Feb. 11, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Fortis Inc. ("Fortis" or the "Corporation") (TSX/NYSE:FTS) has declared the following dividends payable on June 1, 2026 to the Shareholders of Record of the following Shares of the Corporation at the close of business on May 15, 2026: $0.3063 per share on the First Preference Shares, Series "F";$0.3826875 per share on the First Preference Shares, Series "G"; $0.26144 per share on the First

    2/11/26 5:42:27 PM ET
    $FTS
    Electric Utilities: Central
    Utilities

    $AOMR
    $BPMC
    $CF
    $CTT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Shattuck Labs Inc.

    SC 13D/A - Shattuck Labs, Inc. (0001680367) (Subject)

    12/6/24 9:03:38 PM ET
    $STTK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by MP Materials Corp.

    SC 13D/A - MP Materials Corp. / DE (0001801368) (Subject)

    12/4/24 7:57:02 PM ET
    $MP
    Metal Mining
    Basic Materials

    Amendment: SEC Form SC 13G/A filed by Enveric Biosciences Inc.

    SC 13G/A - Enveric Biosciences, Inc. (0000890821) (Subject)

    11/14/24 4:03:47 PM ET
    $ENVB
    Biotechnology: Pharmaceutical Preparations
    Health Care